Guided Therapeutics, Inc. (GTHP)
| Previous Close | 0.1675 |
| Open | 0.1650 |
| Bid | 0.1700 x 0 |
| Ask | 0.1750 x 0 |
| Day's Range | 0.1675 - 0.1750 |
| 52 Week Range | 0.0640 - 0.2470 |
| Volume | |
| Avg. Volume | 5,514 |
| Market Cap | 10.48M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireGuided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China
PEACHTREE CORNERS, Ga., October 22, 2024--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that its Chinese Partner, Shandong Yaohua Medical Instrument Corporation (SMI), has filed its application for LuViva with the Chinese National Medical Products Administration (NMPA). The application included results from 449 women tested at four leading medical institutions in China. The results of the study were above that required for a successful s
Business WireGuided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
PEACHTREE CORNERS, Ga., July 10, 2024--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that leading physicians from four prestigious medical centers have completed their review and signed off on the study results for submission to the Chinese National Medical Products Administration (NMPA). Approximately 460 women were tested with LuViva at four leading hospitals in China. There were no adverse events reported with the use of LuViva during
